Free Newsletter
Expensive Herceptin draws fire in UK
Roche's drug Herceptin has become a lightning rod for debate over cancer treatment in England. Radiotherapists--including the specialty's chief at the National Health Service--are saying that cancer treatment is weighted too heavily toward expensive drugs and not enough toward more cost-effective radiation treatments.
The NHS spent some $206 million on Herceptin last year, and only 500 patients benefited from that chemotherapy, Dr. Peter Kirkbride told the BBC. Spending that kind of money on drugs means the NHS can't invest as much in radiation machines. For the same amount, Kirkbride said, he could have treated 30,000 cancer patients with radiation.
Predictably, radiation-machine manufacturers aren't pleased, either; a trade group spokesman says there's been a "collapse in critical investment." How much of this debate is evidence-based outrage and how much sour grapes? We'll let the NHS decide.
- read the BBC's report
Related Articles:
Roche's Herceptin KO's tumors. Report
UK accepts J&J's money-back guarantee. Report
Roche cuts UK price on cancer drug. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





